Trials / Completed
CompletedNCT00991861
Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis
Double-blind, Randomized, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41007 Once Daily and LAS41007 Twice Daily Versus LAS106521 Gel Twice Daily in the Treatment of Actinic Keratosis Grade I to II
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine the efficacy, safety and tolerability of either a once or twice daily topical application of LAS41007 compared to a twice daily application of LAS106521 in the treatment of actinic keratosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LAS41007 o.d. | Once daily, topical application |
| DRUG | LAS41007 b.i.d. | Twice daily, topical application |
| DRUG | LAS106521 | Twice daily, topical application |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2009-10-08
- Last updated
- 2015-05-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00991861. Inclusion in this directory is not an endorsement.